{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:27:32Z","timestamp":1790440052746,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2003,1]]},"DOI":"10.1007\/s11906-003-0012-2","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T06:51:24Z","timestamp":1179989484000},"page":"59-65","source":"Crossref","is-referenced-by-count":49,"title":["Aldosterone: A risk factor for vascular disease"],"prefix":"10.1007","volume":"5","author":[{"given":"Mario Fritsch","family":"Neves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto L.","family":"Schiffrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","volume":"342","author":"S Yusuf","year":"2000","unstructured":"Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145\u2013153.","journal-title":"N Engl J Med"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995\u20131003.","journal-title":"Lancet"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","volume":"40","author":"M Naruse","year":"2002","unstructured":"Naruse M, Tanabe A, Sato A, et al.: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002, 40:28\u201333. A recent original study providing evidence that aldosterone escape may occur during long-term use of ARBs via activation of AT2 receptors, which may attenuate beneficial effects of these drugs on cardiac tissue. The addition of low-dose spironolactone induced further cardioprotection in ARB-treated rats.","journal-title":"Hypertension"},{"key":"12_CR4","first-page":"293","volume":"55","author":"S Li","year":"2001","unstructured":"Li S, Wu P, Zhong S, Guo Z, et al.: Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone. Horm Res 2001, 55:293\u2013297.","journal-title":"Horm Res"},{"key":"12_CR5","first-page":"761","volume":"86","author":"BM Schmidt","year":"2001","unstructured":"Schmidt BM, Georgens AC, Martin N, et al.: Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system. J Clin Endocrinol Metab 2001, 86:761\u2013767.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1161\/01.HYP.35.5.1099","volume":"35","author":"R Alzamora","year":"2000","unstructured":"Alzamora R, Michea L, Marusic ET: Role of 11b-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 2000, 35:1099\u20131104.","journal-title":"Hypertension"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004872-200105000-00013","volume":"19","author":"JB Park","year":"2001","unstructured":"Park JB, Schiffrin EL: Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001, 19:921\u2013930.","journal-title":"J Hypertens"},{"key":"12_CR8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/00004872-200207000-00014","volume":"20","author":"D Hayoz","year":"2002","unstructured":"Hayoz D: Left ventricular hypertrophy and remodeling of resistance arteries: the role of activation of the renin-angiotensin-aldosterone system in hypertension. J Hypertens 2002, 20:1295\u20131296.","journal-title":"J Hypertens"},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1161\/01.HYP.37.6.1444","volume":"37","author":"JB Park","year":"2001","unstructured":"Park JB, Schiffrin EL: ETA receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosteroneinfused rats. Hypertension 2001, 37:1444\u20131449.","journal-title":"Hypertension"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","volume":"40","author":"A Virdis","year":"2002","unstructured":"Virdis A, Fritsch Neves M, Amiri F, et al.: Spironolactone improves vascular changes and oxidative stress in angiotensin II-infused rats. Hypertension 2002, 40:504\u2013510. This paper demonstrates that vascular remodeling induced in angiotensin II-infused rats is in part mediated by effects of aldosterone stimulated by angiotensin II rather than directly by angiotensin II.","journal-title":"Hypertension"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004872-200207000-00032","volume":"20","author":"ML Muiesan","year":"2002","unstructured":"Muiesan ML, Rizzoni D, Salvetti M, et al.: Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension. J Hypertens 2002, 20:1439\u20131444. This study showed a close correlation between the media-to-lumen ratio of resistance arteries and the relative wall thickness of the left ventricle, greater in renovascular hypertension and primary aldosteronism than in patients with essential hypertension.","journal-title":"J Hypertens"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/01.HYP.35.4.931","volume":"35","author":"D Rizzoni","year":"2000","unstructured":"Rizzoni D, Porteri E, Guefi D, et al.: Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000, 35:931\u2013935.","journal-title":"Hypertension"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1161\/01.HYP.37.6.1444","volume":"37","author":"JB Park","year":"2001","unstructured":"Park JB, Schiffrin EL: ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001, 37:1444\u20131449.","journal-title":"Hypertension"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0008-6363(99)00110-8","volume":"43","author":"GP Rossi","year":"1999","unstructured":"Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999, 43:300\u2013307.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 2","key":"12_CR15","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00005344-200111002-00013","volume":"38","author":"GP Rossi","year":"2001","unstructured":"Rossi GP, Cavallin M, Nussdorfer GG, Pessina AC: The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 2001, 38(Suppl 2):S49-S52.","journal-title":"J Cardiovasc Pharmacol"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0014-5793(02)03017-X","volume":"524","author":"Y Oshima","year":"2002","unstructured":"Oshima Y, Fujio Y, Funamoto M, et al.: Aldosterone augments endothelin-1 induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway. FEBS Lett 2002, 524:123\u2013126.","journal-title":"FEBS Lett"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/hc0602.104675","volume":"105","author":"Y Takeda","year":"2002","unstructured":"Takeda Y, Yoneda T, Demura M, et al.: Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 2002, 105:677\u2013679. Interesting publication that suggests that aldosterone acts in part via stimulation of the calcium-dependent phosphatase calcineurin to induce cardiac hypertrophy.","journal-title":"Circulation"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1161\/01.ATV.20.11.e83","volume":"20","author":"R Martin de","year":"2000","unstructured":"de Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA: The transcription factor NF-kB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000, 20:e83-e88.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"12_CR19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.HYP.35.1.193","volume":"35","author":"DN Muller","year":"2000","unstructured":"Muller DN, Dechend R, Mervaala EMA, et al.: NF-kB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000, 35[part 2]:193\u2013201.","journal-title":"Hypertension"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.HYP.37.2.787","volume":"37","author":"A Fiebeler","year":"2001","unstructured":"Fiebeler A, Schmidt F, Muller DN, et al.: Mineralocorticoid receptor affects AP-1 and nuclear factor-kappaB activation in angiotensin II-induced cardiac injury. Hypertension 2001, 37[part 2]:787\u2013793. In this study using dTGR overexpressing human angiotensinogen and Rennin\u2014an experimental model associated with severe end-organ Damage\u2014spironolactone reduced cardiac fibrosis and expression of inflammatory markers, suggesting that aldosterone mediates effects of angiotensin on cardiac inflammation and fibrosis.","journal-title":"Hypertension"},{"key":"12_CR21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/abbi.2000.2045","volume":"383","author":"V Kolla","year":"2000","unstructured":"Kolla V, Litwack G: Inhibition of mineralocorticoid-mediated transcription by NF-kappaB. Arch Biochem Biophys 2000, 383:38\u201345.","journal-title":"Arch Biochem Biophys"},{"key":"12_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/hy0202.103481","volume":"39","author":"FZ Ammarguellat","year":"2002","unstructured":"Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL: Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 2002, 39:679\u2013684. Endothelin and ETA receptors were shown to mediate inflammation and fibrosis in the heart of rats with mineralocorticoid hypertension.","journal-title":"Hypertension"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/sj.bjp.0704247","volume":"134","author":"K Rombouts","year":"2001","unstructured":"Rombouts K, Wielant A, Hellemans K, et al.: Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 2001, 134:224\u2013232.","journal-title":"Br J Pharmacol"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmcc.2000.1129","volume":"32","author":"P Lijnen","year":"2000","unstructured":"Lijnen P, Petrov V: Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000, 32:865\u2013879.","journal-title":"J Mol Cell Cardiol"},{"key":"12_CR25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/01.CIR.103.2.319","volume":"103","author":"F Ammarguellat","year":"2001","unstructured":"Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in doca-salt hypertensive rats: effect of endothelin ETA receptor antagonism. Circulation 2001, 103:319\u2013324.","journal-title":"Circulation"},{"issue":"2","key":"12_CR26","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0895-7061(01)02291-9","volume":"15","author":"JB Park","year":"2002","unstructured":"Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002, 15(2 Pt 1):164\u2013169. Endothelin and ETA receptors were shown to mediate cardiovascular fibrosis in aldosterone-induced hypertension.","journal-title":"Am J Hypertens"},{"key":"12_CR27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1291\/hypres.24.99","volume":"24","author":"A Sato","year":"2001","unstructured":"Sato A, Takane H, Saruta T: High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 2001, 24:99\u2013104.","journal-title":"Hypertens Res"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, et al.: Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102:2700\u20132706. In this subanalysis of RALES, markers of cardiac fibrosis were associated with poor outcome in heart failure patients. The reduction of these markers by aldosterone receptor antagonism was associated with reduced mortality in these patients.","journal-title":"Circulation"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878. This study suggests that myocardial fibrosis is not a direct effect of aldosterone. Rather, aldosterone may initially induce vascular damage followed by tissue necrosis, with fibrosis occurring subsequently.","journal-title":"Endocrinology"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"38911","DOI":"10.1074\/jbc.M103984200","volume":"276","author":"D Menuet Le","year":"2001","unstructured":"Le Menuet D, Isnard R, Bichara M, et al.: Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. J Biol Chem 2001, 276:38911\u201338920.","journal-title":"J Biol Chem"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","volume":"342","author":"HP Kohler","year":"2000","unstructured":"Kohler HP, Grant PJ: Plasminogen-activator inhibitor type I and coronary artery disease. N Engl J Med 2000, 342:1792\u20131801.","journal-title":"N Engl J Med"},{"key":"12_CR32","first-page":"336","volume":"85","author":"NJ Brown","year":"2000","unstructured":"Brown NJ, Kim K-S, Chen Y-Q, et al.: Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000, 85:336\u2013344.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1210\/jcem.87.2.7980","volume":"87","author":"P Sawathiparnich","year":"2002","unstructured":"Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002, 87:448\u2013452. This study suggested that aldosterone-induced vascular fibrosis may result from effects on PAI-1. Activation of the RAAS provoked increased PAI-1 expression, which was attenuated by aldosterone receptor antagonism, indicating another mechanism by which spironolactone can improve outcome in heart failure patients.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1043-2760(01)00432-5","volume":"12","author":"R Rocha","year":"2001","unstructured":"Rocha R, Stier CT Jr: Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001, 12:308\u2013314.","journal-title":"Trends Endocrinol Metab"},{"key":"12_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00004872-200201000-00017","volume":"20","author":"MP Schlaich","year":"2002","unstructured":"Schlaich MP, Klingbeil AU, Jacobi J, et al.: Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension. J Hypertens 2002, 20:117\u2013124.","journal-title":"J Hypertens"},{"key":"12_CR36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.101.6.594","volume":"101","author":"CAJ Farquharson","year":"2000","unstructured":"Farquharson CAJ, Struthers AD: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I\/angiotensin II conversion in patients with chronic heart failure. Circulation 2000, 101:594\u2013597. This paper shows a possible mechanism for the beneficial effect of spironolactone. The authors demonstrated that spironolactone increases nitric oxide activity and improves endothelial dysfunction in heart failure patients.","journal-title":"Circulation"},{"key":"12_CR37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.jhh.1000737","volume":"13","author":"F Veglio","year":"1999","unstructured":"Veglio F, Molino P, CatGenova G, et al.: Impaired baroreflex function and arterial compliance in primary aldosteronism. J Hum Hypertens 1999, 13:29\u201336.","journal-title":"J Hum Hypertens"},{"key":"12_CR38","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S, Duquaine D, King S, et al.: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212\u20132216. In early diet-induced atherosclerosis, the selective mineralocorticoid receptor antagonist eplerenone attenuated oxidative stress by inhibition of NADPH oxidase and improved endothelial dysfunction.","journal-title":"Circulation"},{"key":"12_CR39","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/014107680109400803","volume":"94","author":"M Epstein","year":"2001","unstructured":"Epstein M: Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001, 94:378\u2013383.","journal-title":"J R Soc Med"},{"key":"12_CR40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R, Chander PN, Zuckerman A, Stier Jr CT: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33[part II]:232\u2013237.","journal-title":"Hypertension"},{"key":"12_CR41","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0272-6386(99)70298-2","volume":"33","author":"M Nishimura","year":"1999","unstructured":"Nishimura M, Uzu T, Fujii T, et al.: Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999, 33:261\u2013266.","journal-title":"Am J Kidney Dis"},{"key":"12_CR42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.123.3195.503","volume":"123","author":"J Genest","year":"1956","unstructured":"Genest J, Lemieux G, Davignon A, et al.: Human arterial hypertension: a state of mild chronic hyperaldosteronism? Science 1956, 123:503\u2013505.","journal-title":"Science"},{"key":"12_CR43","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11906-001-0045-3","volume":"3","author":"M Stowasser","year":"2001","unstructured":"Stowasser M: Primary aldosteronism: rare bird or common cause of secondary hypertension? Curr Hypertens Rep 2001, 3:230\u2013239.","journal-title":"Curr Hypertens Rep"},{"key":"12_CR44","first-page":"1863","volume":"85","author":"CE Fardella","year":"2000","unstructured":"Fardella CE, Mosso L, Gomez-Sanchez C, et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863\u20131867.","journal-title":"J Clin Endocrinol Metab"},{"key":"12_CR45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004872-200201000-00003","volume":"20","author":"PO Lim","year":"2002","unstructured":"Lim PO, Struthers AD, MacDonald TM: The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens 2002, 20:11\u201315. Review article that develops the hypothesis that the neurohormonal state of hypertensive patients changes over time, going from high-normal renin hypertension to an end stage of idiopathic hyperaldosteronism. The authors support the use of the ARR as a screening test of hyperaldosteronism that may allow a larger number of patients to be identified.","journal-title":"J Hypertens"},{"key":"12_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00004872-200103000-00002","volume":"19","author":"M Stowasser","year":"2001","unstructured":"Stowasser M: Primary aldosteronism: revival of a syndrome. J Hypertens 2001, 19:363\u2013366.","journal-title":"J Hypertens"},{"key":"12_CR47","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","volume":"19","author":"PO Lim","year":"2001","unstructured":"Lim PO, Young WF Jr, MacDonald TM: A review of the medical treatment of primary aldosteronism. J Hypertens 2001, 19:353\u2013361.","journal-title":"J Hypertens"},{"key":"12_CR48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(00)04223-9","volume":"357","author":"NM Kaplan","year":"2001","unstructured":"Kaplan NM: Cautions over the current epidemic of primary aldosteronism. Lancet 2001, 357:953\u2013954. The author, a highly experienced hypertension specialist, points out the need to be cautious in interpreting laboratory tests in the quest to diagnose increasing numbers of patients potentially presenting with hyperaldosteronism.","journal-title":"Lancet"},{"key":"12_CR49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00004872-200106000-00022","volume":"19","author":"GS Stokes","year":"2001","unstructured":"Stokes GS, Monaghan JC, Ryan M, Woodward M: Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J Hypertens 2001, 19:1161\u20131165.","journal-title":"J Hypertens"},{"key":"12_CR50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.RES.86.1.37","volume":"86","author":"AS Mihailidou","year":"2000","unstructured":"Mihailidou AS, Bundgaard H, Mardini M, et al.: Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na+-K+ pump. Circ Res 2000, 86:37\u201342.","journal-title":"Circ Res"},{"key":"12_CR51","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1161\/01.HYP.0000025904.23047.27","volume":"40","author":"AS Mihailidou","year":"2002","unstructured":"Mihailidou AS, Mardini M, Funder JW, Raison M: Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia. Hypertension 2002, 40:124\u2013129.","journal-title":"Hypertension"},{"key":"12_CR52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123. Important paper that provides support to the idea that mineralocorticoid blockade may provide additional effects on top of renin-angiotensin blockade.","journal-title":"Hypertension"},{"key":"12_CR53","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141:3871\u20133878.","journal-title":"Endocrinology"},{"key":"12_CR54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1011119003788","volume":"15","author":"B Pitt","year":"2001","unstructured":"Pitt B, Williams G, Remme W, et al.: The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001, 15:79\u201387.","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0012-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-003-0012-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-003-0012-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:04Z","timestamp":1559434564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-003-0012-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11906-003-0012-2","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]}}}